Published April 2018 | Version v1
Journal article

Knockdown of survivin results in inhibition of epithelial to mesenchymal transition in retinal pigment epithelial cells by attenuating the TGFβ pathway

  • 1. Department of Anatomy, Histology and Embryology, Fudan University, Shanghai (China)
  • 2. Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN, 38163 (United States)
  • 3. Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, TN, 38163 (United States)
  • 4. Department of Genetics, University of Tennessee Health Science Center, Memphis, TN, 38163 (United States)
  • 5. Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163 (United States)

Description

Highlights: • TGFβ activates BIRC5 expression in RPE cells. • Knockdown of BIRC5 results in the suppression of EMT in RPE cells. • Reduction of survivin attenuates TGFβ pathway in RPE cells. • Inhibition of TGFβ pathway downregulates survivin expression in RPE cells. Proliferative vitreoretinopathy (PVR) is a common complication of open globe injury and the most common cause of failed retinal detachment surgery. The response by retinal pigment epithelial (RPE) cells liberated into the vitreous includes proliferation and migration; most importantly, epithelial to mesenchymal transition (EMT) of RPE plays a central role in the development and progress of PVR. For the first time, we show that knockdown of BIRC5, a member of the inhibitor of apoptosis protein family, using either lentiviral vector based CRISPR/Cas9 nickase gene editing or inhibition of survivin using the small-molecule inhibitor YM155, results in the suppression of EMT in RPE cells. Knockdown of survivin or inhibition of survivin significantly reduced TGFβ-induced cell proliferation and migration. We further demonstrated that knockdown or inhibition of survivin attenuated the TGFβ signaling by showing reduced phospho-SMAD2 in BIRC5 knockdown or YM155-treated cells compared to controls. Inhibition of the TGFβ pathway using TGFβ receptor inhibitor also suppressed survivin expression in RPE cells. Our studies demonstrate that survivin contributes to EMT by cross-talking with the TGFβ pathway in RPE cells. Targeting survivin using small-molecule inhibitors may provide a novel approach to treat PVR disease.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.bbrc.2018.03.021

Additional details

Identifiers

DOI
10.1016/j.bbrc.2018.03.021;
PII
S0006291X18304959;

Publishing Information

Journal Title
Biochemical and Biophysical Research Communications
Journal Volume
498
Journal Issue
3
Journal Page Range
p. 573-578
ISSN
0006-291X
CODEN
BBRCA9

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
54056542
Subject category
S60: APPLIED LIFE SCIENCES;
Descriptors DEI
CELL PROLIFERATION; INJURIES; RECEPTORS; RHODOPSIN; SURGERY
Descriptors DEC
DISEASES; MEDICINE; MEMBRANE PROTEINS; ORGANIC COMPOUNDS; PIGMENTS; PROTEINS

Optional Information

Copyright
Copyright (c) 2018 Elsevier Inc. All rights reserved.